Trial
NCT03166176
Phase II Trial of Vistusertib（AZD2014） Single Agent in TSC1or 2 Null or TSC 1/2 Mutation Solid Cancer Patients Refractory to Standard Chemotherapy
Phase IIWITHDRAWNEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Samsung Medical Center
Collaborators
—
Condition
Solid Tumor
Intervention
Vistusertib(AZD2014)
Why stopped
lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-05-20